Scancell Holdings’ (LON:SCLP) Dr Cliff Holloway talks to Proactive London’s Katie Pilbeam after being awarded funds from Innovate UK to produce a COVID-19 vaccine.
Holloway explains how the company is using their immunotherapies knowledge which is used in their cancer research projects to help with the COVID-19 drive.
Alongside this the company’s lead drug, SCIB-1 to treat skin cancer has recently entered a phase II clinical trial in the UK.
